Speaker Name: 
Malignant Hem Debates “Back to the future: should we be using gemtuzumab ozogamycin in induction therapy for AML?” David Rizzieri, MD, Professor vs Thomas Leblanc, MD, Associate Professor “DLBCL front line treatment--dinosaurs can be CHOPped but are we
143 Jones Bldg
Durham, NC 27701
United States
Room Number: 
143 Jones Bldg
Session date: 
Wednesday, June 20, 2018 - 7:30am to 9:00am
  • 1.50 AMA PRA Category 1 Credit(s)
  • 1.50 Attendance

Please login or register to take this course.